The unit(s) of measurement applicable to the metric.
: Metric tonnes (t)
Indicator
i
Indicators were developed by WBCSD. Learn more on the Methodology page.
: Pollutants released to environment
Metric type
i
The category of nature-related metrics. Learn more on the Methodology page.
: Pressure
Framework alignment notes
i
The details of a metric’s alignment to each framework, including where the same or similar metric can be found within the listed framework.
ESRS E2-4 28a
TNFD C2.0
GRI 306-3-b, GRI 101-6-c
SBTN: Nutrient application to soils (from fertilizer application)
Other pollution loading to soil (e.g., acidification or toxic chemicals)
Refer to AMR's Shared Goals for alignment to metric
GBF Target 7, Target 11
Target example
i
An example target and the target source are presented to illustrate how a target could be set for this metric. Learn more on the Methodology page.
[Company name] will reduce [pollutant type] in [ecosystem/location] by [target amount, in absolute tonnes, or percentage] by [target year], compared to a [baseline year] baseline.
Target source: WBCSD target template
Sector
i
Each metric applies to one sector.
Pharmaceutical
Value chain stage
i
Each metric applies to one or more stages of the value chain aligned with the associated actions.
Raw MaterialsManufacturingEnd of Life
Metric assessment
i
The relevance and feasibility scores were determined by WBCSD member companies. Learn more on the Methodology page.
Relevance:High
Feasibility:Medium
Related actions
i
The other actions that the metric is mapped to.
Reduce water and soil pollution risk from APIs, especially antibiotics, harmful chemicals and other relevant substances from manufacturing sites
Reduce air, water and soil pollution (including non-GHG emissions) from agriculture-related pharmaceutical manufacturing feedstocks by engaging with suppliers and encouraging the adoption of less polluting methods in alignment with a Science Based Targets Network (SBTN) Landscape Engagement Target
Reduce APIs (including antibiotics) in the environment by investing in and supporting the development of technologies that enhance the removal of pharmaceutical residues from wastewater